A pilot study showed that nivolumab (an anti-PD-1 antibody) produced superior clinical and radiographic responses in five r/r PCNSL or secondary CNS lymphoma (SCNSL) patients. The gene discussed is PDCD1; the disease is primary central nervous system lymphoma.